

**Information Governance**  
Wrightington Hospital  
Hall Lane  
Appley Bridge  
Lancashire  
WN6 9EP

Tel: 01257 256284  
Email: FOI@wwl.nhs.uk  
Web: www.wwl.nhs.uk

Ref: FOI2019/5655

Date Received: 13<sup>th</sup> September 2019

Response Due: 11<sup>th</sup> October 2019

8<sup>th</sup> October 2019

Dear

## **INFORMATION REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000**

**You asked:**

**1. Does your trust treat Hereditary angioedema HAE?**

No

**2. In the last 6 months, how many patients with Hereditary angioedema (HAE) have been treated with,**

- **Berint**
- **Cinryze**
- **Firazyr**
- **Ruconest**
- **Takhzyro**
- **Tranexamic acid**
- **Other**

None

**3. Does your trust treat Immune thrombocytopenia purpura ITP?**

Yes

**4. Over the past 6 months, how many patients with persistent / chronic\* Immune thrombocytopenia purpura [ITP] have you treated [include all treatments such as steroids, splenectomy, immune globulins, Rituximab and TPOs]?**

50 patients were treated during the period 1<sup>st</sup> March 2019 – 31<sup>st</sup> August 2019

5. Over the past 6 months, how many patients with persistent / chronic\* Immune thrombocytopenia purpura [ITP] were new to treatment with the following;

- Eltrombopag [Revolade]
- Romiplostim [Nplate]

Less than five.

6. At what line of treatment would you currently use a TPO in an ITP patient: 4th line, 3rd line, 2nd line or 1st line?

2<sup>nd</sup> or 3<sup>rd</sup> line usually.

7. Over the past 6 months, how many patients have you treated with the following

	Total patients	Eltrombopag [Revolade]	Romiplostim [Nplate]
Immune thrombocytopenia purpura [ITP]	28	17	10
Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy	None		
Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation	<5	<5	
Chemotherapy induced thrombocytopenia (CIT)	None		
Myelodysplastic syndromes (MDS)	None		

Conditions and treatments. If None, please state None.

I trust that this information is helpful to you, however if you are not entirely satisfied with this response please do not hesitate to contact the Information Governance Department on 01257 488271. If we do not hear from you within 28 days we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Andrew Foster  
Chief Executive

PLEASE NOTE:

The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication, would require the permission of the copyright holder. You must ensure you gain their permission before reproducing any third party information.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Wrightington Hospital, Hall Lane, Appley Bridge, Wigan, WN6 9EP

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. Generally the ICO cannot make a decision unless you have exhausted the complaints procedure at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF